Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;59(2):70-75.
doi: 10.11622/smedj.2018014.

Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management

Boon Hui Chan  1 , Ruixiang Yee  1 , Rukshini Puvanendran  2 , Seng Bin Ang  2
Affiliations

Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management

Boon Hui Chan et al. Singapore Med J. 2018 Feb.

Abstract

Osteoporosis is a major, growing healthcare issue. This is especially of concern in an ageing population like that of Singapore. Osteoporotic patients are at risk of fractures, which can result in increased morbidity and mortality. The use of antiresorptive therapy with bisphosphonates or denosumab has been proven to reduce fracture risk. However, the use of these medications has rarely been associated with the development of osteonecrosis of the jaw, a potentially debilitating condition affecting one or both jaws. Appropriate understanding of the patient's antiresorptive therapy regime, as well as early institution of preventive dental measures, can play an important role in preventing medication-related osteonecrosis of the jaw (MRONJ). Regular monitoring and prompt referral to specialist care is warranted for patients with established MRONJ.

Keywords: MRONJ; bisphosphonates; osteonecrosis; osteoporosis.

PubMed Disclaimer

Figures

Box 1
Box 1
Risk of developing MRONJ:
Fig. 1
Fig. 1
Flowchart shows the recommended management of osteoporotic patients. Definitive and restorative procedures include dental extractions, dental implant placement and prosthetic treatment. MRONJ: medication-related osteonecrosis of the jaw
Box 2
Box 2
Dental treatment for patients on antiresorptive therapy:(9,20,21,27,28)
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. WHO Technical Report Series 921. Prevention and Management of Osteoporosis: Report of a WHO Scientific Group [online] [Accessed January 9, 2018]. Available at: http://apps.who.int/iris/bitstream/10665/42841/1/WHO_TRS_921.pdf .
    1. Ministry of Health Singapore. Osteoporosis: MOH Clinical Practice Guidelines 3/2008. [Accessed January 9, 2018]. Available at: https://www.moh.gov.sg/content/dam/moh_web/HPP/Doctors/cpg_medical/withd... .
    1. Lau EM, Lee JK, Suriwongpaisal P, et al. The incidence of hip fracture in four Asian countries: The Asian Osteoporosis Study (AOS) Osteoporos Int. 2001;12:239–43. - PubMed
    1. Koh LK, Saw SM, Lee JJ, Leong KH, Lee J, National Working Committee on Osteoporosis Hip fracture incidence rates in Singapore 1991-1998. Osteoporos Int. 2001;12:311–8. - PubMed
    1. WHO. Fracture Risk Assessment. [Accessed January 9, 2018]. Available at: https://www.sheffield.ac.uk/FRAX/

MeSH terms